New Drug Offers Hope in Extending Survival for HER2-Positive Breast Cancer Patients

A pivotal clinical trial co-led by Professor Nadia Harbeck, Director of the Breast Center at LMU University Hospital, has shown promising results in extending the lives of patients with advanced HER2-positive breast cancer, particularly those with brain metastases. The study, recently published in the journal, Nature Medicine, highlights the success of an innovative antibody-drug conjugate (ADC) called trastuzumab deruxtecan.

You must be healthcare professional to view this content.

EXPLORE

POMConnect Banner2 Email Bottom

Copyright © 2024 DocMed Technology Pte Ltd. All rights reserved.